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Abstract
Background: Herpes zoster (HZ) is a significant cause of morbidity and complications in adult renal transplant
recipients. We determined the incidence, complications and risk factors for the development of HZ after renal
transplantation in a setting using universal antiviral prophylaxis.
Methods: The medical files of all adult renal transplants, performed between 2004 and 2008, were retrospectively
reviewed to assess the clinical characteristics and risk factors of HZ. Incident cases of HZ were determined and the
probability of developing post-transplant HZ for all subjects was calculated using the Kaplan Meier method. A
multivariable Cox proportional hazards model was applied to assess the risk factors associated with the
development of HZ.
Results: A total of 450 patients were eligible with a median follow up of 38 months. Twenty nine subjects (6.4 %)
developed HZ, the median time to onset was 18 months, only three of them (10.3 %) required hospitalization, and none
developed disseminated or visceral disease and death directly attributed to zoster. However, high rates of post-herpetic
neuralgia (48.7 %) were observed. Overall incidence was calculated at 20.6 cases per 1000 patient-years of follow-up.
Following multivariate analysis, increased age≥ 60 years old, positive pre-transplant history of varicella related disease and
administration of rejection treatment conferred an increased risk of 4.00-fold (CI: 1.79- 8.92), 16.00-fold (CI: 4.62- 55.52), and
5.57-fold (CI: 1.56- 19.84) respectively, for the development of post-transplant zoster.
Conclusions: HZ remains a common complication after renal transplantation in adults under current immunosuppession
protocols and universal antiviral prophylaxis.
Keywords: Herpes zoster, HZ, Incidence, Complications, Post- herpetic neuralgia, PHN, Risk factors, Renal transplantation,
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Background
Herpes zoster (HZ) represents the reactivation of the vari-
cella zoster virus (VZV), which establishes lifelong latency
in cranial- nerve or dorsal-root ganglia after the primary
infection that had caused chickenpox [1, 2]. The risk of HZ
increases with impaired specific cell mediated immunity
mainly as a result of advancing age [3–6] or acquired im-
munosuppression [7–11]. It has been estimated that the
incidence of HZ in solid organ transplant (SOT) patients is
10- to 100-fold higher than in the general population,
ranging between 18.3 to 55.1 cases per 1000 person-years,
with lung and heart recipients appearing to be at highest
risk [12, 13]. The most common manifestation of VZV re-
activation in SOT is cutaneous HZ, involving ≤ 2 adjacent
dermatomes, however, atypical clinical findings, dissemi-
nated disease, visceral involvement and lethal outcome have
been described [14]. In addition, 20-40 % of the transplant
recipients will develop post-herpetic neuralgia (PHN) as a
secondary complication, significantly greater than the rate
in immunocompetent populations [13].
Risk factors for the development of HZ in SOT have not
been well defined due to the lack of large prospective trials.
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Longitudinal studies have demonstrated that older age, race
and type of transplant may increase the rates of HZ in solid
organ recipients [12, 15]. The development of novel im-
munosuppressive agents has dramatically improved the sur-
vival of all SOT recipients, including renal transplant
patients, however, there is accumulating evidence that the
use of the above agents may more frequently induce certain
viral infections, including VZV [16–20]. Although existing
studies have not been designed or powered to determine
the effect of specific immunosuppressive agents or respect-
ive combinations on VZV incidence, mycophenolate mofe-
til (MMF) has been suggested as potential risk factor [20].
According to updated clinical practice guidelines, the
live attenuated herpes zoster vaccine (Zostavax®, Merck
& Co., Inc., USA) is recommended to pre- transplant
candidates aged ≥ 60 years and varicella-positive candi-
dates aged 50-59 years who are not severely immuno-
compromised if transplantation is not expected within
4 weeks [21].
The aim of the present study was to evaluate the inci-
dence, complications and risk factors for the develop-
ment of HZ in a large, single- center renal transplant
cohort using current immunosuppressant and antiviral
prophylaxis protocols.
Methods
Patient population and study design
We reviewed the records of all adult patients who
underwent renal transplantation (RT) between January
1st, 2004 and December 31st, 2008 at the Renal Trans-
plant Unit of “Laiko” General hospital, in Athens,
Greece. This is a tertiary hospital, where more than 40 %
of the country’s kidney transplantations are performed.
All patients originate from Central and Southern Greece
and remain under regular follow up by the above trans-
plant unit. Demographic, clinical and laboratory infor-
mation were abstracted from the patients’ medical
records and included the following: Age, gender, time of
transplant, type of donor, immunosuppressive protocol,
episodes of acutegraft rejection, history of VZV related
disease, pre-transplant VZV serologic status, antiviral
prophylaxis, distribution of HZ and related complica-
tions, including hospital admission. The diagnosis of HZ
was clinical and was based on the characteristic signs
and symptoms, including the classic appearance and
distribution of the rash. Post-herpetic neuralgia was
defined as pain persisting in the affected area for more
than 30 days after the development of the rash. The date
of last data collection was February 28th, 2009 which
allowed for a minimum follow up of two months for
each patient. Individuals with early loss of graft and
follow-up or survival of less than 2 months after RT
were excluded from the analysis. In order to clarify fur-
ther their pre- transplantation history of varicella or HZ,
all patients were contacted by telephone. At this point,
they were informed about the aim of the present study
and a verbal consent was obtained. The study protocol
was approved by the institution review board of “Laiko”
General Hospital.
Immunosuppressive regimen
The immunosuppressive regimens for induction therapy
after RT included anti-interleukin (IL)-2 receptor antibody
(basiliximab or daclizumab) or anti-thymocyte globulin
(ATG). Triple combinations of various immunosuppressive
agents including tacrolimus (TAC) or cyclosporine (CsA),
mycophenolate mofetil or mycophenolate sodium (MPA),
everolimus or rapamune (mTORi) and methylprednizolone
(MD), were used as maintenance therapy.
Herpesvirus prophylaxis
Antiviral prophylaxis was prescribed to all RT recipients ac-
cording to donor and recipient cytomegalovirus (CMV) sta-
tus. All CMV- IgG positive recipients were treated with a
seven day course of intravenous ganciclovir, at a dose of
125 mg/kg, followed by three months of oral valganciclovir,
with dose adjustments according to the patient’s creatinine
clearance. Patients who were CMV- IgG negative and re-
ceived an allograft from a CMV- IgG positive donor were
treated with the same protocol for six months. Finally, re-
cipients who were CMV-IgG negative and their donor was
also CMV-IgG negative did not receive any prophylaxis.
Statistical analysis
Statistical package for the social sciences (SPSS) version
18 was used to conduct the statistical analysis and p-
value <0.05 was considered statistically significant. Con-
tinuous and categorical variables were summarized as
appropriate. Differences of the continuous variables be-
tween patients who developed HZ and those who did
not, were analyzed using Mann–Whitney tests when the
assumptions required by the parametric counterpart
tests were not met andthe primary endpoint was the in-
cident of HZ. The incident rates of HZ were estimated
by the number of HZ’s incidents developed in our
cohort, divided by the sum of the person-time of the
transplanted population. The probability of developing
post-transplant HZ for all subjects and between sub-
groups of interest was calculated using the Kaplan Meier
method. Log-rank tests and Walt test (Cox model) were
used for comparison of the probability of developing
post-transplant HZ between groups of interest. To deter-
mine risk factors for the development of HZ following
KT, univariate and multivariable Cox proportional haz-
ards model were used. Cox proportional hazards regres-
sion was used to model the association of the incident of
HZ to patients and clinical characteristics and to
estimate hazard ratios (HRs) along with their 95 %
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confidence intervals (CIs). In multivariate models, with the
use of the forward selection method, with removal criterion
of 10 %, the association to outcome of each of these factors
in the presence of the others in the model was explored.
For analyses, available predictor variables included: age,
gender, pre-transplant history of VZV, induction agent,
rejection treatment and immunosuppressive regimen.
Immunosuppressive regimen was analyzed as a time-
dependent variable in the Cox regression model.
Post-transplant zoster development was also used as a time-
dependent effect in mortality and graft failure Cox models.
Results
Characteristics of kidney transplant recipients
A total of 479 adults underwent RT over the study period.
Τwenty-eight were excluded from the analysis because of
lack of follow up for at least 60 days post- transplantation.
One additional patient was excluded because he received
both kidney and liver transplantation. Finally, 450 patients
with a mean age of 45 ± 13 (range 18-73) years at trans-
plantation were eligible for further analysis. The characteris-
tics of these patients are presented in Table 1. Eleven deaths
(2.44 %) occurred during the study period, eight of those
(72.8 %) with functioning graft. As illustrated, a great pro-
portion of the study population (44.7 %) lacked information
regarding history of varicella or HZ before transplantation,
collected either from medical records or by telephone inter-
view. Moreover, pre- transplant VZV serology was not avail-
able for any of the participants, as this was not a standard
requirement in our department at the time of the present
study. According to clinical data available for 252 patients,
the majority (79.7 %) reported a pre-transplant varicella
related disease. Of these, 180 patients reported a positive
history of chickenpox, while the remaining twenty- one
suffered an episode of pre-transplant zoster. Two of the
latter presented a recurrence of HZ post- transplantation.
No patient was vaccinated against varicella before trans-
plantation, as the respective vaccine was only licensed in
2008 in our country.The participants’ immunosuppressive
regimens were recorded at 3, 6, 12 and 18 months
post- transplantation and are presented in Table 2. As
shown, mycophenolate mophetil or mycophenolate sodium
were included in the great majority of the patients’ immuno-
suppressive regimens, at all time points.
Herpes zoster events
Twenty- nine out of 450 eligible kidney recipients
(6.4 %) developed HZ during the study period, and the
mean time to onset was 22.21 ± 14.49 months (median
18 months, range 5-58). The mean age of the patients who
manifested zoster was higher when compared to the age of
those who did not (median age 50 versus 45 years old;
Mann–Whitney test p-value = 0.006). The clinical character-
istics of these patients are illustrated in Table 3. All episodes
involved a single dermatome, there were no recurrences nor
disseminated disease and no patient sustained primary
varicella infection. As shown, the majority (89 %) re-
ceived oral antiviral treatment and were managed as
outpatients, two subjects had a positive history of pre-
transplantation HZ and 48 % suffered PHN. None of
the 21 CMV-IgG negative recipients who received graft
by a CMV-IgG negative donor, developed zoster.
The cumulative probability of HZ using the Kaplan-
Meier method was 0.7 % at 6 months, 1.6 % at 12 months,
5 % at 24 months, 6.8 % at 36 months and 10.7 % at
Table 1 Clinical characteristics of kidney transplant patients, (n= 450)
Characteristics N (%)
Age at transplantation (years) 45 ± 13
<60 377 (83.8)




Follow up time (months); median (range) 38 (2-71)
Type of donor
Live related donor 192 (42.7)








Anti-thymocyte globulin 23 (5.1)
None 14 (3.1)
Death at last follow-up
No 439 (97.6)
Yes 11 (2.4)
Graft functionality at death
Unknown 1 (9.1)
Graft in function 8 (72.7)
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60 months following transplantation (Fig. 1). The estimated
total incidence rate of HZ was 20.6 cases per 1000 person-
years based on the exact time each person contributed on
the study.
Furthermore, we analyzed the cumulative incidence of
HZ in two separate age groups; those younger than 60 ver-
sus those equal or older than 60 years at time of transplant.
In the younger age group, the cumulative incidence of HZ,
using the Kaplan-Meier method, was 0.3 % at 6 months,
1.1 % at 12 months, 4.5 % a
t 24 months, 6.2 % at 36 months and 6.8 % at 60 months.
In the older group, the respective incidence increased
from 2.9 % at 6 months, to 4.3 % at 12 months, 7.7 % at
24 months, 10.1 % at 36 months and 56.4 % at 60 months
following transplantation (log-rank p-value = 0.014, see
Additional file 1: Figure S1). The overall incidence of HZ
was higher for patients ≥60 years old throughout the en-
tire follow-up period. In particular, the estimated average
incidence rate of HZ in patients < 60 years of age was
16.7 cases per 1000 person- years, while in patients ≥
60 years, 43 cases per 1000 person- years, respectively.
Herpes zoster risk factor analysis
Univariate analysis was performed to determine whether
age at transplantation, gender, history of pre-transplant
VZV related disease, induction agent and rejection treat-
ment were risks for the development of HZ (Table 4.).
By modelling age as categorical variable, patients ≥ 60 years
old conferred a 2.598-fold increased risk for HZ develop-
ment when compared to those aged < 60 years (CI 1.180 -
5.721; p-value = 0.018). In contrast, no association of HZ
and gender was detected, however, we observed a trend of
increased probability for zoster in women after the first year
post-transplant (see Additional file 1: Figure S2). Patients
with a pre- transplant history of VZV related disease
were 6.22-fold more likely to develop HZ when com-
pared to those with negative history (CI 0.844- 45.847;
p-value =0.07, Table 4). As shown in Additional file 1:
Figure S3, the risk increased with time post-
transplantation. No significant association between
induction agent and risk for HZ was observed. Finally,
no interaction was noted between the different im-
munosuppressive regimens or between rejection treat-
ment and the risk for post- transplant HZ, when
analyzed by use of time dependent models. However, in
patients who received rejection treatment the risk for
HZ was slightly increased.
Table 2 Immunosuppressive regimen according to follow-up time in kidney transplant patients, (n = 450)
3 months N (%) 6 months N (%) 12 months N (%) 18 months N (%)
TAC/MPA/MP 212 (47.1) 217 (48.2) 215 (47.8) 210 (46.7)
CsA/MPA/MP 145 (32.2) 144 (32.0) 131 (29.1) 114 (25.3)
TAC/mTORi/MP 72 (16) 60 (13.3) 53 (11.8) 50 (11.1)
CsA/mTORi/MP 1 (0.2) 1 (0.2) 1 (0,2) 0 (0)
MPA/mTORi/MP 16 (3.6) 15 (3.3) 24 (5,3) 24 (5,3)
Double immunosuppressive regimen 2 (0.4) 3 (0.7) 15 (3,3) 36 (8.0)
None/unknown 2 (0.4) 10 (2.2) 11 (2.4) 16 (3.6)
TAC: tacrolimus; MPA: mycophenolatemofetil or mycophenolate sodium; MP: methylprednisolone; CsA: cyclosporine; mTORi: rapammune or everolimus
Table 3 Characteristics of herpes zoster in kidney transplant
patients (n = 29)
Characteristics N (%)
Time to onset (months): median (range) 18 (4 - 58)
Age (years): mean ± SD 52 ± 12
Distribution
Lumbosacral 6 (20.7)




















SD: standard deviation; VZV: varicella zoster virus; PHN: post- herpetic neuralgia
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Following multivariate analysis, age group (<60 or ≥
60 years) at time of transplant and positive pre-
transplant history of VZV remained statistically signifi-
cant risk factors for HZ. In particular, individuals ≥
60 years old presented an increased by 3.0 % risk, while
those with positive pre-transplant history of VZV an in-
creased by 15.0 % probability of shingles when compared
to the individuals with a respective negative history, fol-
lowing transplantation. Moreover, patients who received
anti-rejection treatment were 5.6 times more likelyto de-
velop HZ when compared to those who did not receive
such treatment (Table 4).
When the development of HZ was analyzed as time-
dependent covariate, a statistically significant increased
mortality was found in patients who developed HZ com-
pared to those that did not. In specific, patients who
developed HZ had an 8.076-fold increased mortality ver-
sus those who did not (CI: 2.079-31.376; p-value = 0.003,
Finally, there was no evidence of increased graft failure
among subjects manifesting post-transplant zoster.
Discussion
The present study provides information about the epi-
demiology of herpes zoster among adult renal trans-
plant patients in the country’s largest transplant center,
over a five- year period. This transplant unit uses a
consistent immunosuppression protocol along with
universal prophylaxis against cytomegalovirus, while all
renal recipients receive long term follow up by the
same medical team. Our results revealed an overall in-
cidence rate of HZ of 20.6 cases per 1000 person-years,
while age ≥ 60 years at time of transplant, positive pre-
transplant history of varicella- zoster related disease and
administration of anti- rejection treatment were identified
as significant risk factors for the development of shingles;
most HZ cases were managed as outpatients, there was no
disseminated disease, however, a high proportion of indi-
viduals suffered post-herpetic neuralgia.
The incidence of post-transplant HZ seems to differ
according to transplant organ probably reflecting the
various levels of induced immunosuppression. Conse-
quently, a higher incidence of HZ has been observed
among heart transplants, followed by kidney and finally,
liver transplants who generally require less immunosup-
pression [22]. Estimates for overall zoster incidence in
renal transplants have ranged between 24.7 and 44.6 per
1000 person-years in previous retrospective studies, but
these variations mostly indicate the intensity of im-
munosuppression as well as the differences between the
prophylactic antiviral protocols [12, 15, 20, 23]. The
respective incidence rate among our study population,
albeit lower, is comparable to Arness et al. [15], who
have also used induction therapy and antiviral prophy-
laxis against CMV in the great majority of their patients.
Fig. 1 Cumulative probability of herpes zoster after kidney transplantation
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Despite the retrospective data collection in the present
study, it is unlikely that the true incidence of zoster is
underestimated, since all patients had continuing follow-
up by the same team of doctors.
The time to zoster development in SOT has been previ-
ously reported between 6.6 months to 4.9 years, while in
our group of patients the respective median onset time
was 18 months [15, 19, 23, 24]. It is evident that these var-
iations probably reflect differences in follow-up time and
therefore, prolonged immunosuppression. As shown be-
fore [15], when we used the Kaplan-Meier method to
evaluate the probability of developing HZ in the post
transplant period, we found that this probability, although
very low (0.7 %) in the first six months, increased rapidly
over time, reaching 10.7 % after five years.
The majority of the 29 individuals who developed zoster
following transplantation experienced mild disease, involv-
ing a single dermatome and were managed as outpatients.
Only three patients required hospitalization because of in-
tense pain, vomiting and dehydration. However, we report
a high rate of PHN (48.3 %) contrary to other authors who
have reported PHN between 5-42 % of solid organ recipi-
ents [15, 19]. Risk factors for postherpetic neuralgia include
older age and greater severity of the prodrome, rash, and
pain during the acute phase [25]. Our findings cannot be
attributed to the difference in the age distribution between
the group of patients who developed PHN and those who
did not, since the mean age between the two groups was
similar. It is noteworthy, however, that all three subjects
needing hospitalization, experienced PHN.
Interestingly, we observed an 8.076-fold increased mor-
tality risk in patients who developed zoster compared to
those who did not, and this was not directly related to viral
infection mortality. To the best of our knowledge, this has
not been reported before, however, this should be inter-
preted cautiously since it was only based on few events and
was not addressed in the multivariate analysis. A possible
explanation could be that post-transplant VZV reactivation
is an independent indicator of over-immunosuppression
per se, thus predisposing to higher mortality; this is also
consistent with the fact that we did not have any evidence
of increased graft failure among the individuals with zoster.
Age has been a traditional risk factor for zoster among
immunocompetent as well as among adults with im-
munosuppression [12, 15, 26, 27]. Our data confirmed
that age equal or greater than 60 years at transplant-
ation, conferred an increased by 3 % risk for VZV reacti-
vation when compared to the younger age group.
Women, especially those belonging to older age
groups, have been described to be at increased risk for
zoster in the general population [28]. It has not been
clarified though, whether female gender represents a
true biological mechanism of susceptibility or this may
be attributed to increased disease documentation, since
women with zoster appear to seek medical advice more
often than men [29]. We only identified an increased
trend of zoster among our female transplant recipients
after the first year post- transplant.
We demonstrated that pre-transplant VZV related
disease was a statistically significant risk factor for shin-
gles following transplantation. As the large majority of
adults who undergo transplantation have likely experi-
enced varicella during childhood, it would possibly be
more appropriate to link post- transplant HZ to zoster
events before transplantation. However, there is uncer-
tainty about the degree and duration of protection from
previous HZ in healthy persons, and even more so
Table 4 Univariate and multivariate Cox analysis of risk factors
for the development of herpes zoster in kidney transplant
patients, (n = 450)





< 60 1.00 (referent)
≥ 60 2.598 1.180 - 5.721 0.018
Gender
Female 1.00 (referent) - -
Male 0.671 0.323-1.396 0.286
Pre-transplant VZV disease
No/Unknown 1.00 (referent) - -
Yes 10.777 3.262-35.612 0.0001
Induction agent
None 1.00 (referent) - -
Anti-thymocyte
globulin (ATG)
0 0- n.ea 0.977
Basiliximab 0.36 0.81-1.612 0.182
Daclizumab 0.39 0.89-1.709 0.211
Rejection treatment
No 1.00 (referent) - -
Yes 2.08 0.624-6.930 0.233
Multivariate analysis
Age, (years)
< 60 1.00 (referent)
≥ 60 3.995 1.790-8.915 0.001
Pre-transplant VZV disease
No/Unknown 1.00 (referent) - -
Yes 16.022 4.624-55.522 0.008
Rejection treatment
No 1.00 (referent) - -
Yes 5.566 1.562-19.835 0.0001
an.e.: not estimated
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among those with immunosuppression, since the thresh-
old under which HZ occurs is unknown [30–32]. Recent
advances in the understanding of the pathogenesis of
HZ indicate that, besides cell-mediated immunity dys-
function, additional factors including co-infection with
different strains of VZV and genetic susceptibility may
have a role in the reactivation of the latent virus [30].
Since the information of pre-transplant VZV related dis-
ease was mainly self reported and there were only few
individuals with zoster events prior to transplant, we
chose to link the risk of VZV related disease as a whole,
in our cohort. As shown recently, 92.5 % of unvaccin-
ated Greek adults of younger age, presented serologic
evidence of immunity against chickenpox. In particular,
seropositivity was identified in 100 % of those with posi-
tive, but also in 53 % and 91 % of those reporting a
negative or unknown history of disease, respectively
[33]. More than half of our patients reported a negative
or unknown history of varicella or zoster, therefore, in
accordance with the above findings, we can assume that
the correlation of positive pre-transplant history of VZV
related disease with post-transplant zoster is underesti-
mated in our analysis.
Intensive immunosuppression including induction or
acute anti- rejection treatment has been associated with
increased risk of zoster [19, 22]. In particular, the use of
MPA has been described as a risk factor for zoster by
some investigators [15]. However, this has not been a
consistent finding, as the scientific evidence concerning
the risk of specific immunosuppressive agents or combi-
nations for the development of HZ in SOT remains in-
sufficient. As shown, no such association was found in
our study population, and this could be attributed to the
fact that the great majority of our patients were treated
with one of the MPA’s during the whole study period as
was also the case with induction treatment. In contrast,
anti-rejection therapy conferred a significantly increased
risk for zoster in the post-transplant period, and this,
despite the fact that the incidence of acute rejection
among our study participants was extremely low (2.7 %).
According to previous investigators, pre-emptive ra-
ther than universal prophylaxis against CMV increases
the risk of zoster following SOT [20, 34]. As our patients
were on prophylactic antiviral treatment and no one re-
ceived pre-emptive, we were not able to demonstrate
any similar effect. Nevertheless, one could speculate that
universal prophylaxis may have contributed to the
delayed onset of zoster among our population.
The epidemiology of HZ among both healthy and im-
munocompromised individuals will remain an ongoing
challenge in the advent of the aging population, the use
of novel immunosuppressive agents and the implemen-
tation of universal vaccination against primary varicella
in childhood. According to recent data, the incidence of
HZ among the general population has decreased [35]
following prophylactic varicella vaccination in childhood,
however, other investigators report an increased herpes
zoster incidence in a setting of increased varicella vac-
cine coverage [36]. It is evident that continuous surveil-
lance and research are needed to demonstrate how the
lack of natural boosting will affect SOT patients. In
Greece, varicella vaccination has been introduced in the
National Immunization Program since 2008 while the
live attenuated vaccine against herpes zoster (Zostavax®,
Merck & Co., Inc., USA) was licensed in October 2014,
awaiting official recommendations. The latter, has been
shown to be safe and protective in the immunocompe-
tent elderly population [37]. Despite recent guidelines
proposing the use of Zostavax among certain groups of
immunocompromised adults, there has been no study
evaluating whether pre-transplant immunization against
HZ would decrease the risk of post-transplant zoster in
SOT [21, 31, 38]. Herein, additional issues to be ad-
dressed include limited vaccine efficacy in patients with
end stage renal disease awaiting transplantation as well
as optimal time interval between vaccine administration
and transplantation in terms of safety. An investigational
adjuvanted subunit vaccine (called HZ/su, GlaxoSmithKline
Biologicals) has proven safe and effective among older
healthy adults and if studied in the SOT population, it
might prove a useful alternative to the live attenuated vac-
cine because of the reduced risk of disease resulting from
replication [39].
Study limitations and strengths
This study has a number of limitations. It was a retrospect-
ive, single center study and can, therefore, not be general-
ized. In addition, as pre-transplant VZV serology was not
available for any of our patients, self reported VZV related
disease, being also subject to recall bias, underestimates the
proportion of subjects with primary immunity against
VZV. Finally, it is evident that in a larger study many of the
trends that appeared when evaluating risk factors might be
different. Despite the above limitations, this is the first
study to provide data about the epidemiology, complica-
tions and risk factors for the development of HZ in renal
transplant recipients in our country.
Conclusions
In the present study we have shown that HZ is a fre-
quent cause of morbidity among adult renal transplant
recipients in the country’s largest transplant center, that
uses a consistent immunosuppression and a universal
antiviral prophylaxis protocol. Among our transplant
patients with zoster, we observed high rates of PHN and
a higher risk of mortality that was not directly related to
acute VZV disease. The latter should be interpreted with
caution as this was not addressed in multivariate
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analysis. Older age, history of pre-transplant VZV re-
lated disease and use of anti- rejection treatment were
identified as independent risk factors for shingles follow-
ing transplantation. In view of the recent licensure of
the live attenuated vaccine Zostavax in our country,
along with the updated recommendations for vaccin-
ation of the immunocompromised, the above results
may provide useful evidence in order to design optimal
strategies to prevent HZ among individuals awaiting
renal transplantation.
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